美(mei)國新澤西(xi)州(zhou)普林斯頓和中(zhong)國上(shang)海2008年6月25日(ri)電 /新華美(mei)通(tong)/ -- 藥明(ming)(ming)康(kang)德(de) (NYSE: WX) 和科(ke)文斯 (NYSE: CVD) 今日(ri)宣布雙(shuang)方簽(qian)訂諒解備忘(wang)錄，將(jiang)在(zai)中(zhong)國組(zu)建合(he)資(zi)(zi)公(gong)司(si)（各(ge)占50%股權(quan)），以提(ti)供(gong)世界級的前臨床合(he)同(tong)研究服務(wu)。初步規劃該(gai)合(he)資(zi)(zi)公(gong)司(si)將(jiang)設(she)(she)于中(zhong)國蘇州(zhou)一處面積達323,450平方英尺(chi)的企(qi)業設(she)(she)施(shi)內，目前該(gai)設(she)(she)施(shi)正由藥明(ming)(ming)康(kang)德(de)興建。該(gai)先進設(she)(she)施(shi)完(wan)全按照美(mei)國食品藥品管理局要求和國際標準設(she)(she)計，將(jiang)于2009年竣工，建成后(hou)(hou)將(jiang)提(ti)供(gong) GLP 標準的毒(du)理、藥物代謝和生(sheng)物化學服務(wu)。除了藥明(ming)(ming)康(kang)德(de)負責(ze)提(ti)供(gong)的企(qi)業設(she)(she)施(shi)之外，科(ke)文斯預計首(shou)期將(jiang)投資(zi)(zi)約3000萬美(mei)元。該(gai)合(he)資(zi)(zi)公(gong)司(si)的財務(wu)及(ji)組(zu)織架構詳情(qing)，預計將(jiang)于今年稍(shao)后(hou)(hou)時間待雙(shuang)方約定明(ming)(ming)確(que)條款并(bing)正式組(zu)建實體后(hou)(hou)透露(lu)。

(Logo: //www.nyhomeapp.cn/sa/200708281726.jpg )

“該(gai)合(he)(he)資公(gong)司將(jiang)促使中(zhong)國(guo)領先(xian)的(de)實驗(yan)室(shi)研究和(he)開發(fa)(fa)服(fu)務供應商(shang)與世(shi)界較(jiao)大(da)的(de)上市(shi)合(he)(he)同(tong)研發(fa)(fa)外(wai)包服(fu)務商(shang)建(jian)(jian)立起強大(da)的(de)合(he)(he)作伙伴關(guan)(guan)系，”Joe Herring 先(xian)生，科(ke)文(wen)(wen)斯(si)董事(shi)長兼首席執行官稱(cheng)。“科(ke)文(wen)(wen)斯(si)和(he)藥(yao)明(ming)康(kang)德共同(tong)履行這樣一個承(cheng)諾(nuo)，即對質量、人才以及將(jiang)客(ke)戶關(guan)(guan)系建(jian)(jian)立在(zai)信(xin)任和(he)業(ye)績(ji)基礎上的(de)不懈追求。科(ke)文(wen)(wen)斯(si)領先(xian)市(shi)場的(de)高品質前臨床服(fu)務業(ye)務，聯合(he)(he)藥(yao)明(ming)康(kang)德世(shi)界水平的(de)新藥(yao)研發(fa)(fa)服(fu)務，使我(wo)們(men)能夠在(zai)中(zhong)國(guo)為全球制藥(yao)公(gong)司和(he)生物技(ji)術公(gong)司客(ke)戶提(ti)供卓越的(de)藥(yao)物開發(fa)(fa)方案。”

“我(wo)們很(hen)高興能(neng)與(yu)世(shi)界較大(da)、服(fu)務齊(qi)全面的(de)(de)藥物(wu)開發(fa)服(fu)務公司(si)科文斯合(he)作，”藥明康德董(dong)事長(chang)兼首(shou)席執行(xing)官李革博士稱。“我(wo)們將(jiang)(jiang)能(neng)第(di)一(yi)時間利(li)用(yong)科文斯公司(si)國際一(yi)流(liu)水平的(de)(de)專業(ye)知識(shi)和全球網絡，并加速將(jiang)(jiang)全方位的(de)(de)前臨床服(fu)務和 GLP 標準的(de)(de)毒理(li)服(fu)務的(de)(de)能(neng)力引入該設施的(de)(de)進程。這(zhe)次合(he)作伙伴(ban)關系對于我(wo)們建立(li)全球性研發(fa)外包(bao)服(fu)務平臺(tai)(tai)的(de)(de)使命至關重要，借助這(zhe)個(ge)平臺(tai)(tai)我(wo)們將(jiang)(jiang)最終(zhong)幫助我(wo)們的(de)(de)合(he)作伙伴(ban)提高藥物(wu)發(fa)現(xian)的(de)(de)成(cheng)功率，縮短藥物(wu)開發(fa)的(de)(de)時間。”

中(zhong)(zhong)(zhong)國(guo)(guo)(guo)(guo)(guo)市(shi)(shi)場(chang)在(zai)提(ti)供高質量的(de)新藥研發(fa)外包服(fu)務行(xing)(xing)業(ye)越(yue)來(lai)越(yue)具吸(xi)引力。許(xu)多跨國(guo)(guo)(guo)(guo)(guo)制藥公(gong)(gong)司(si)(si)、生(sheng)物技術公(gong)(gong)司(si)(si)及(ji)醫療器械公(gong)(gong)司(si)(si)已經(jing)入駐(zhu)中(zhong)(zhong)(zhong)國(guo)(guo)(guo)(guo)(guo)，旨在(zai)其迅(xun)速(su)擴大的(de)醫療保健市(shi)(shi)場(chang)上分一杯羹；利用其病(bing)患人口眾多這(zhe)一條件(jian)進行(xing)(xing)全(quan)球(qiu)試(shi)驗；以及(ji)分享其龐大的(de)外包研發(fa)工(gong)作人才庫。因此，前(qian)臨床服(fu)務在(zai)中(zhong)(zhong)(zhong)國(guo)(guo)(guo)(guo)(guo)市(shi)(shi)場(chang)可望在(zai)未來(lai)數(shu)年快速(su)成長。藥明康德和科文(wen)斯(si)組建(jian)的(de)合資(zi)公(gong)(gong)司(si)(si)將使(shi)雙方的(de)客戶充(chong)分利用在(zai)中(zhong)(zhong)(zhong)國(guo)(guo)(guo)(guo)(guo)進行(xing)(xing)前(qian)臨床研究和開發(fa)的(de)優(you)勢，并有(you)可能(neng)提(ti)交全(quan)球(qiu)和國(guo)(guo)(guo)(guo)(guo)內藥品申請(qing)。

關于藥明康德

藥(yao)(yao)明(ming)康(kang)(kang)德(de)，總部位于(yu)中(zhong)國(guo)上海(hai)并在(zai)美國(guo)和中(zhong)國(guo)都有(you)運(yun)營(ying)實體，是(shi)全(quan)球領先(xian)的制(zhi)(zhi)藥(yao)(yao)、生(sheng)(sheng)物(wu)技術以(yi)及醫療(liao)(liao)器(qi)械研(yan)發(fa)(fa)外包服務公(gong)司。作為一(yi)家(jia)以(yi)研(yan)究(jiu)為首任，以(yi)客戶(hu)為中(zhong)心的公(gong)司，藥(yao)(yao)明(ming)康(kang)(kang)德(de)向全(quan)球制(zhi)(zhi)藥(yao)(yao)公(gong)司、生(sheng)(sheng)物(wu)技術公(gong)司以(yi)及醫療(liao)(liao)器(qi)械公(gong)司提供一(yi)系列(lie)全(quan)方位的實驗室研(yan)發(fa)(fa)，研(yan)究(jiu)生(sheng)(sheng)產(chan)，生(sheng)(sheng)物(wu)制(zhi)(zhi)劑(ji)測試(shi)以(yi)及生(sheng)(sheng)產(chan)服務，服務范圍貫穿制(zhi)(zhi)藥(yao)(yao)和醫療(liao)(liao)器(qi)械研(yan)發(fa)(fa)全(quan)過程。藥(yao)(yao)明(ming)康(kang)(kang)德(de)的服務旨在(zai)幫助其全(quan)球合作伙伴縮短藥(yao)(yao)物(wu)及醫療(liao)(liao)器(qi)械研(yan)發(fa)(fa)周期、降低研(yan)發(fa)(fa)成本(ben)。欲了(le)解更多藥(yao)(yao)明(ming)康(kang)(kang)德(de)的信息，請瀏覽： //www.wuxipharmatech.com 。

關于科文斯

美(mei)國科文(wen)斯有限公司，總部(bu)位(wei)于新(xin)澤西州普林斯頓，是世界上(shang)規模(mo)較大、服(fu)務齊全(quan)面的(de)(de)藥(yao)物開(kai)發服(fu)務公司之一，年收入超(chao)過15億美(mei)元，在全(quan)球20多個國家擁有運營(ying)實體(ti)，擁有員工8,900多名(ming)。欲了(le)解科文(wen)斯的(de)(de)產品(pin)和服(fu)務，最近的(de)(de)新(xin)聞發布(bu)，以及提交至證券交易委員會的(de)(de)資料，請瀏覽公司網站： //www.covance.com 。

Statements contained in this press release, which are not historical facts, such as statements about the nature, scope and timing and benefits of the planned joint venture as well as the attractiveness of China for delivering outsourced discovery and development services, the growth of the China market and advantages of conducting preclinical research and development in China are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements including the statements contained herein are based largely on Covance and WuXi PharmaTech management’s expectations and actual results could vary significantly. The memorandum of understanding is non-binding and subject to negotiation of definitive documentation. The nature, scope and timing of the venture could change and definitive arrangements may not be agreed to by the parties. Success of the venture and the attractiveness of China, including for delivering outsource discovery and development services, are subject to other risks and uncertainties including, without limitation, competitive factors, outsourcing trends in the pharmaceutical industry, levels of industry research and development spending, the joint venture’s ability to build and staff the facility and to market and provide the services in China, and other factors described in Covance’s and WuX PharmaTech’s filings with the U.S. Securities and Exchange Commission. Neither Covance nor WuXi PharmaTech undertake any duty to update any forward looking statement to conform the statement to actual results or changes in expectations.